A Closer Look at Five Stocks in Spotlight Following Financial Reports

Brookdale Senior Living, Inc. (NYSE:BKD) is in spotlight after the company posted a net loss of $0.19 per share for the second quarter, versus estimates of a loss of $0.12. On the other hand, its revenue stood at $1.26 billion and topped the estimates by $30 million. Adjusted CFFO was $123.4 million for the second quarter, an increase of 12.2% from the second quarter of 2015. The company re-affirmed its full year CFFO guidance in the range of $455 million to $475 million, while EBITDA is expected to be in range of $870 to $890 million.  The number of funds from our database with positions in Brookdale Senior Living, Inc. (NYSE:BKD) fell to 45 from 57 during the first quarter of 2016.

Callon Petroleum Company (NYSE:CPE)’s stock has gained over 4% on the back of the company reporting its second-quarter results. The company posted revenue of $45.15 million, below the consensus estimate of $$47.75 million, but adjusted EPS of $0.05 topped the expectations by $0.01. Callon also reported an increase of 8% on the quarter in its net daily production to 13,451 barrels. At the end of March, 29 hedge funds tracked by us had long positions in Callon Petroleum Company (NYSE:CPE).

Finally, Clovis Oncology Inc (NASDAQ:CLVS)’s stock is nearly 7% in the green after the biopharmaceutical company reported a net loss of $2.07 per share for the second quarter, versus expectations of a loss of $2.10. The company did not have any revenue and said it had $378.5 million in cash, cash equivalents and available-for-sale securities at the end of June. “We are pleased to have completed the submission of our NDA for rucaparib in the treatment of advanced ovarian cancer in late June. […] We continue to focus on our broader clinical development program for rucaparib, and are actively preparing for a potential U.S. launch of rucaparib,” Patrick J. Mahaffy, President and CEO of Clovis Oncology was quoted as saying in a statement. Heading into the second quarter, 24 funds tracked by Insider Monkey were bullish on Clovis Oncology Inc (NASDAQ:CLVS).

Disclosure: None